An Open-Label Pilot Trial To Collect And Evaluate Data On The Use Of Migranal [dihydroergotamine mesilate] In The Treatment Of Two Acute Migraine Attacks Associated With Cutaneous Allodynia
Latest Information Update: 12 Mar 2022
Price :
$35 *
At a glance
- Drugs Dihydroergotamine mesilate (Primary)
- Indications Migraine
- Focus Therapeutic Use
- 13 Oct 2011 Actual end date Aug 2009 added as reported by ClinicalTrials.gov.
- 13 Oct 2011 Actual initiation date Aug 2006 added as reported by ClinicalTrials.gov.
- 13 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.